Teachers Retirement System of The State of Kentucky Buys New Stake in Humana Inc. (NYSE:HUM)

Teachers Retirement System of The State of Kentucky bought a new stake in shares of Humana Inc. (NYSE:HUM – Get Rating) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,095 shares of the insurance provider’s stock, valued at approximately $5,869,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HUM. Starboard Value LP purchased a new stake in Humana during the first quarter valued at approximately $421,332,000. Bank of New York Mellon Corp raised its holdings in shares of Humana by 63.1% in the third quarter. Bank of New York Mellon Corp now owns 1,692,255 shares of the insurance provider’s stock worth $821,065,000 after buying an additional 654,681 shares during the last quarter. Voya Investment Management LLC raised its holdings in shares of Humana by 701.3% in the second quarter. Voya Investment Management LLC now owns 543,394 shares of the insurance provider’s stock worth $254,347,000 after buying an additional 475,584 shares during the last quarter. Putnam Investments LLC raised its holdings in shares of Humana by 5,251.9% in the third quarter. Putnam Investments LLC now owns 469,253 shares of the insurance provider’s stock worth $227,677,000 after buying an additional 460,485 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Humana in the first quarter worth $151,766,000. Hedge funds and other institutional investors own 93.38% of the company’s stock.

Insider Buying and Selling at Humana

In other Humana news, insider Joseph C. Ventura sold 2,048 shares of the stock in a transaction on Monday, February 27th. The shares were sold at an average price of $507.97, for a total transaction of $1,040,322.56. Following the transaction, the insider now directly owns 4,256 shares of the company’s stock, valued at $2,161,920.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Humana news, Director David A. Jr/Ky Jones sold 15,000 shares of Humana stock in a transaction dated Wednesday, December 21st. The shares were sold at an average price of $501.72, for a total transaction of $7,525,800.00. Following the transaction, the director now directly owns 42,028 shares of the company’s stock, valued at $21,086,288.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph C. Ventura sold 2,048 shares of Humana stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $507.97, for a total transaction of $1,040,322.56. Following the transaction, the insider now directly owns 4,256 shares in the company, valued at $2,161,920.32. The disclosure for this sale can be found here. Insiders have sold a total of 34,623 shares of company stock valued at $17,456,436 over the last ninety days. Corporate insiders own 0.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Humana from $575.00 to $562.00 and set a “buy” rating for the company in a report on Tuesday, February 28th. The Goldman Sachs Group raised shares of Humana from a “neutral” rating to a “buy” rating and raised their price target for the stock from $575.00 to $652.00 in a report on Tuesday, December 13th. TheStreet lowered shares of Humana from a “b” rating to a “c+” rating in a research note on Wednesday, February 1st. Truist Financial cut their price objective on shares of Humana from $580.00 to $560.00 and set a “hold” rating on the stock in a research note on Tuesday, February 7th. Finally, Stephens cut their price objective on shares of Humana from $625.00 to $590.00 and set an “overweight” rating on the stock in a research note on Friday, February 3rd. Two analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $594.12.

Humana Stock Performance

HUM opened at $495.55 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.59. The company has a market cap of $61.93 billion, a price-to-earnings ratio of 22.48, a PEG ratio of 1.21 and a beta of 0.72. Humana Inc. has a 52-week low of $410.87 and a 52-week high of $571.30. The firm’s fifty day simple moving average is $494.78 and its two-hundred day simple moving average is $507.39.

Humana (NYSE:HUM – Get Rating) last posted its quarterly earnings data on Wednesday, February 1st. The insurance provider reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.16. The business had revenue of $22.44 billion for the quarter, compared to the consensus estimate of $22.45 billion. Humana had a net margin of 3.02% and a return on equity of 20.50%. The company’s revenue was up 6.6% compared to the same quarter last year. During the same period last year, the firm posted $1.24 earnings per share. Equities analysts anticipate that Humana Inc. will post 28.04 earnings per share for the current fiscal year.

Humana Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 0.71%. This is an increase from Humana’s previous quarterly dividend of $0.79. The ex-dividend date is Thursday, March 30th. Humana’s dividend payout ratio (DPR) is presently 14.29%.

About Humana

(Get Rating)

Humana Inc engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts.